Published 2 days ago • loading... • Updated 2 days ago

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

On Wednesday, June 3, 2026, Antengene Corporation Limited announced it will present the first preclinical data for ATG-207 at the European Congress of Rheumatology in London from June 3 to 6.
Antengene developed ATG-207 to address T cell-mediated autoimmune diseases where existing anti-inflammatory therapies fail to eliminate pathogenic effector T cells and restore durable immune tolerance.
The program utilizes the proprietary AnTenGager platform, featuring '2+1' bivalent binding and TGFβRIII-biased activity, and preclinical studies demonstrated substantially lower proinflammatory cytokine release compared to unbiased fusion protein controls.
To date, Antengene has obtained 32 investigational new drug approvals in the U.S. and Asia, alongside new drug application approvals in 10 Asia Pacific markets, positioning the company across multiple regulatory jurisdictions.
The EULAR 2026 poster presentation scheduled for June 6, 2026, will detail ATG-207's receptor binding, T cell receptor modulation, and regulatory T cell induction in models of T cell-mediated autoimmune disease.

Insights by Ground AI

43 Articles

Bennington Banner

+42 Reposted by 42 other sources

Center

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological…

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year